Announcements Trials
Browse Landscape

Phase

Phase 2 3Phase 1 2

Status

Completed 1Active not recruiting 1

Sponsor Class

OTHER 2

Study Type

Interventional 2

Sponsor

Cancer Type

Plasma cell 1Other hematologic neoplasm 1

Conditions

Multiple Myeloma 1Leukemia, Plasma Cell 1Adenoma, Islet Cell 1

Interventions

pembrolizumab 257Cyclophosphamide 241Specimen Handling 198fludarabine 173Magnetic Resonance Spectroscopy 173Biopsy 147Nivolumab 119Carboplatin 97Radiotherapy 92Paclitaxel 85venetoclax 82Cisplatin 80Gemcitabine 79fludarabine phosphate 78Injections 68Ipilimumab 64Dexamethasone 61atezolizumab 59Bevacizumab 58Cetuximab 57Radiation 55Fluorouracil 55Azacitidine 55durvalumab 54Radiosurgery 52Temozolomide 47Rituximab 44Oxaliplatin 44Irinotecan 43Docetaxel 43

Date Range

30 days90 days1 yearAll

Options

Has results Has announcements

Clinical Trials

2 trials
RecentStart dateEnrollment
Phase 1 × montanide ISA 51 × 1 year × Clear all
NCT02334865 2026-05-15

SVN53-67/M57-KLH Peptide Vaccine in Treating Patients With Newly Diagnosed Multiple Myeloma Receiving Lenalidomide Maintenance Therapy

Roswell Park Cancer Institute

Phase 1 Active not recruiting
18 enrolled
Other hematologic neoplasmPlasma cell

Leukemia, Plasma Cell, Multiple Myeloma

NCT03879694 2026-02-06

Survivin Long Peptide Vaccine in Treating Patients With Metastatic Neuroendocrine Tumors

Roswell Park Cancer Institute

Phase 1 Completed
19 enrolled

Adenoma, Islet Cell

Data powered by HemOnc (CC BY 4.0) Colophon âš¡